In the phase III DETERMINATION trial, progression-free survival was significantly improved with triplet induction therapy and early transplantation in newly diagnosed patients with multiple myeloma, but overall survival at 5 years was similar to the nontransplant approach. The findings were presented at the Plenary Session of the 2022 ASCO Annual Meeting by Paul G. Richardson, MD, Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute and the RJ Corman Professor of Medicine at Harvard Medical School, Boston. “The addition of transplant to novel agent triplet induction therapy using lenalidomide, bortezomib, and dexamethasone [RVd] followed by lenalidomide maintenance until disease progression resulted in a highly significant increase in progression-free survival, with an improvement in the median of over 21 months. Remarkably, despite this advantage, overall survival with follow-up that is now approaching a median of 7 years proved similar between the two arms,” Dr. Richardson reported.
展开▼